"If it ain't broke, don't fix it," goes the old adage, which Rice University professor James Chappell completely ignored in a ...

“If it ain’t broke, don’t fix it,” goes the old adage, which Rice University professor James Chappell completely ignored in a recent Nature Communications publication. In the study, Chappell describes ...

Astrivax BV has raised €30 million (US$30.1 million) in a seed round to take forward the development of a novel vaccine technology that combines a plasmid vector with a replication-competent virus.

Adeno-associated virus (AAV) vectors play a pivotal role in gene therapy, delivering therapeutic genes with high precision and safety. However, a significant challenge in the biomanufacturing of these ...

DNA vaccines, wherein a new antigen is inserted into a validated vector, have tremendous potential for deployment in pandemic applications as they can be rapidly produced in a validated, ...